A study testing doses of BI 764532 in people with a DLL3 positive brain tumor
Official title: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing how much of a drug called BI 764532 people with a brain tumor can handle.
Read our full plain-language summary
What the trial team says
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is continued. During this time, participants visit the study site at regular intervals. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include staying to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.
Key facts
- Registry number
- NCT05916313
- Stage of testing
- Phase 1
- Conditions studied
- Glioma
Where it is running
This trial lists 12 sites.
-
Austria
- Salzburg Cancer Research Institute (Salzburg)
-
California
- University of California Irvine (Orange)
-
Germany
- Universitätsklinikum Frankfurt (Frankfurt)
- Klinikum der Universität München AÖR (München)
- Universitätsklinikum Tübingen (Tübingen)
-
Netherlands
- Erasmus Medisch Centrum-ROTTERDAM-50697 (Rotterdam)
-
Spain
- Hospital del Mar (Barcelona)
- Hospital Universitario 12 de Octubre (Madrid)
-
Switzerland
- Cantonal Hospital of Aarau (Aarau)
- University Hospital of Lausanne (Lausanne)
- University Hosp. Zurich (Zurich)
-
Tennessee
- SCRI Oncology Partners (Nashville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.